Nasdaq Pstx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) and AIM ImmunoTech (NYSE:AIM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Valuation and Earnings This table compares Poseida […]

Poseida Therapeutics (NASDAQ:PSTX – Free Report) had its target price upped by HC Wainwright from $15.00 to $20.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ FY2027 earnings at ($1.03) EPS. Separately, Cantor Fitzgerald […]

Poseida Therapeutics (NASDAQ:PSTX – Free Report) had its price objective increased by HC Wainwright from $15.00 to $20.00 in a research note released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ FY2027 earnings at ($1.03) EPS. Separately, Cantor Fitzgerald restated an […]

Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) and Turnstone Biologics (NASDAQ:TSBX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends. Earnings and Valuation This table compares Poseida […]

Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Free Report) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 3,030,000 shares, a decrease of 22.1% from the October 15th total of 3,890,000 shares. Currently, 5.7% of the company’s stock are sold short. Based on an average trading volume […]